A US Appeals Court overturned a lower court's decision in favor of Life Technologies predecessor firm Applera, clearing the way for it to pursue a claim for "substantial damages."
The latest suit alleges that the BD MAX system infringes upon several patents owned by Gen-Probe related to its Tigris molecular diagnostics blood-screening system
As part of its request for dismissal, MIT admitted no wrongdoing, but agreed to be bound by any court ruling against the case's other defendants, the Whitehead Institute for Biomedical Research and the University of Massachusetts Medical School.
Celera's BHL subsidiary had filed a suit last month against a competing firm and former employees for conspiring to steal clients and employees. The parties have been discussing a possible settlement as they head toward a trial, currently scheduled for May.
The matter is of particular importance since UMass is the only one of the four organizations to which the IP is assigned to have licensed it to companies other than Alnylam.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
